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ABSTRACT
Background. Elevation of the tumor marker S-100B in
melanoma patients is a highly speciﬁc indicator of
recurrence.
Materials and methods. The role of S-100B in disease-
free survival (DFS) was evaluated in stage III melanoma
patients (staged with ﬂuorodeoxyglucose positron emission
tomography [FDG-PET] and computed tomography [CT])
with palpable lymph node metastases who underwent
therapeutic lymph node dissection. S-100B and LDH were
measured on the day before surgery (d =- 1) and on days
1, 2, and 7 postoperatively. Multivariate logistic regression
was used to study factors associated with preoperative
elevation of S-100B. Univariate (log-rank test) and multi-
variate (Cox regression) survival analyses were performed
to identify factors associated with DFS.
Results. Between 2004 and 2008, 56 patients (median age
57, range 24–93) years, 27 males (48%) and 29 females
(52%) entered the study. Preoperative S-100B elevation
was found in 27 patients (48%) and elevated LDH in 20
patients (36%). No association was found between these
two markers at any time. Multivariate analysis showed that
elevated S-100B preoperatively (hazard ratio [HR] 2.7,
P = .03) was associated with DFS. S-100B elevation was
associated with increased tumor size (odds ratio [OR] 3.40;
P = .03).
Conclusion. Elevated S-100B preoperatively in patients
with optimally staged clinical stage III melanoma is asso-
ciated with decreased disease-free survival. S100-B could
be used as a prognostic marker in the stratiﬁcation of new
adjuvant trials to select stage III melanoma patients for
adjuvant systematic treatment.
The incidence of melanoma is still increasing in the
Netherlands. Between 1989 and 2003, the incidence
increased from 9.5 to 13.7/100,000 in men and from 13.4 to
18.5/100,000 in women.
1 About 90% of the patients had
stage I or II melanoma.
2 After surgical treatment, 20–28%
of melanoma patients present with locoregional recurrence
or regional dermal metastases, 26–60% with regional
recurrences, and 15–50% with distant metastases.
3 Despite
improved public awareness as well as early diagnosis and
treatment, mortality from melanoma increased from 2.5 to
3.6/100,000 in men and from 2.0 to 2.4/100,000 in women
in the Netherlands between 1989 and 2003.
1
It is impossible to predict the metastatic behavior of
melanoma inindividual patients. Atpresent, the Multicentre
Selective Lymphadenectomy Trial (MSLT II) is investi-
gating whether sentinel lymph node biopsy reduces the risk
of locoregional metastases and improves survival.
4 In
patients with clinical stage III melanoma (palpable lymph
node metastases), 5-year survival varied between 26 and
67%.
5 Recent staging studies with whole-body ﬂuorode-
oxyglucose positron emission tomography (FDG-PET) and/
orspiralcomputedtomography(CT)inpatientswithclinical
stage III melanoma have shown that about one quarter of
these patients had distant metastases.
6,7 Furthermore, the
uptakeofFDGinthelymphnodemetastasesinpatientswith
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value.
8 FDG-PET or spiral CT improved the staging of
clinical stage III melanoma and led to better selection of
patients for therapeutic lymph node dissection.
6,7
Serum lactate dehydrogenase (LDH) had high speciﬁc-
ity for melanoma, but low sensitivity. It was an
independent prognostic factor in stage IV melanoma.
9–12
Increased S-100B concentrations were ﬁrst detected in
melanoma patients in 1980.
13 Later, S-100B was found to
be a serological tumor marker for melanoma and is mostly
increased in stage III and IV.
14,15
S-100B is a 21 kilodalton (kDa) protein that was ﬁrst
isolated from the central nervous system in vertebrates. The
name is derived from its 100% solvency in saturated
ammonium sulfate with neutral pH. It has calcium-binding
properties and as a dimer, consists of two isomers a and b.
All possible combinations can occur (S-100aa, S-100ab,S -
100bb).
15 The S-100B protein is of neuroectodermal and
mesodermal origin and is expressed in various parts of the
body. S-100B is chieﬂy found in glial cells and Schwann
cells.
16 Serum S-100B can be measured with an immuno-
radiometric assay (Sangtec 100 IRMA/RIA assay) or with
an immunoluminometric assay (LIA Mat Sangtec 100).
This study addressed the question whether the periop-
erative measurement of the tumor markers S-100B has
prognostic value in FDG-PET and spiral CT staged patients
with stage III melanoma who are selected for therapeutic
lymph node dissection.
MATERIALS AND METHODS
Patients
Melanoma patients, earlier staged AJCC I and II, now
presenting with clinically and cytologically proven regional
nodal metastases of melanoma (AJCC stage IIIb and IIIc)
were staged with whole-body FDG-PET (Siemens ECAT
EXACT HR ? scanner) and with 64-slice spiral CT (Sie-
mens Somatom Sensation). Sentinel node positive patients
and patients with regional dermal metastases were excluded
for this study. The patients whose test results were negative
for distant metastases were eligible for therapeutic lymph
node dissection with curative intent. Nodal metastases
of C 3c ma n d / o rC 3 positive lymph nodes and/or extra
nodal growth received adjuvant radiotherapy (20 9 2.4
Gy).
17,18 LDH and S-100B were measured preoperative (day
-1) and postoperative days 1, 2, and 7. The study was
approved by the Medical Ethical Committee of the UMCG.
Methods
LDH was analyzed routinely by means of Roche Mod-
ular (Hitachi) with an enzymatic activity measurement;
normal values of LDH were considered to be\250 U/L.
Concentrations of S-100B were measured using Sangtec
100 immunoassay on the Advantage (Nichols).
The S-100B half-life is estimated to be 30 min.
19
Approximately 10 times the half-life after lymph node
dissection, S-100B values should reduce to the minimum
possible. When tumor cells are still present the release of
S-100B will continue or may even increase. Therefore,
S-100B levels were measured on days -1, 1, 2, and 7.
Levels were calculated on the basis of a calibration
curve and checked against internal standards with a known
concentration of S-100B. In this assay, a cut-off point of
0.15 g/L was set. The reference values for the S-100B
assay (Liason Sangtec 100) were established by analysis of
S-100B values of 120 healthy men and women according
to the CLSI C28A2 guideline. Concentrations within this
range were considered to be normal, whereas concentration
above this range were considered to be elevated. A post-
operative increase of S-100B was deﬁned as any increase
on the postoperative days 1, 2, or 7 (day 1 as baseline
value, elevation on day 2 compared with day 1, and/ or
elevation on day 7 compared with day 2).
Statistics
Data were analyzed with STATA version 10.0. Logistic
regression analysis was used to assess factors associated
with elevated S-100B concentrations. Factors associated
with disease-free survival (DFS) were analyzed with
standard univariate (log-rank test) and multivariate (Cox
proportions hazard) survival methods.
RESULTS
Patients
In the period from January 2004 to January 2008, 56
patients (27 males [48%] and 29 females [52%]), median
age 57 (range 24–93) years underwent therapeutic lymph
node dissection (Table 1). Preoperatively, 27 patients had
elevated S-100B concentrations (48%), while 20 patients
had increased LDH levels (36%). The range on day -1, 1,
2, and 7 for S-100B was 0.03–23.3, 0.02–1.5, 0.03–0.82,
0.01–0.22 and for LDH 109–428, 106–816, 108–335, 115–
802. No associations were found between S-100B and LDH
levels on days -1, 1, 2, and 7 (P = .45, P = .87, P = .84,
and P = .90, respectively). The S-100B concentration
normalized postoperatively in 22 of the 27 patients (81.4%)
and the LDH in 18 of the 20 patients (90%).
Preoperative S-100B elevation was associated with
increased lymph node size (odds ratio [OR] 3.4, P = .03),
however not signiﬁcantly with extranodal growth (P = .8),
3456 S. Kruijff et al.more than 2 positive lymph nodes (P = .5), age (P = .6),
or gender (P = .6) (Table 2).
Disease-Free Survival
During a median follow-up of 14.2 months (range 0.6–
40.9) months, tumor recurrence was diagnosed in 24
patients (43%), of which 17 patients were diagnosed with
distant metastasis and 7 patients with a regional recurrence.
As shown in Table 3, DFS was not associated with sex,
localization of the lymph node, or the size of the lymph
nodes. Two-year DFS in patients with elevated preopera-
tive S-100B concentrations was 34% versus 61% for
patients without elevated preoperative S-100B concentra-
tions (hazard ratio [HR] 2.6, P = .03). In the patients
whose S-100B increased postoperatively, 2-year DFS was
30% versus 51% for patients without a postoperative S-
100B increase (HR 2.0, P = .1) (Fig. 1).
In multivariate analysis (model with positive lymph
nodes, extranodal growth, preoperative and postoperative
S-100B and substage IIIb or IIIc), extranodal growth (HR
0.4, P = .05), and elevated preoperative S-100B concen-
trations (HR 2.6, P = .03) were signiﬁcantly associated
with decreased DFS. Patients with increasing postoperative
S-100B serum levels showed a trend toward statistical
signiﬁcance when correlated to DFS (HR 2.6, P = .07).
DISCUSSION
This is the ﬁrst study that demonstrates a potential
prognostic value of preoperative S-100B concentrations in
patients who underwent a therapeutic lymph node dissec-
tion after preoperative staging with FDG-PET and CT.
According to the literature, the proportions of patients with
elevated S-100B concentrations were 0–9% in stage I/II,
TABLE 1 Characteristics of 56 AJCC stage III melanoma patients
Variable Patients Percentage
Gender
Male 27 48.2
Female 29 51.8
Median age (years) 57.0
Localization primary tumor
Trunk 24 42.8
Head and neck 3 5.3
Upper extremities 7 12.5
Lower extremities 22 55.8
Breslow thickness primary tumor
T1 (\1.0 mm) 7 12.5
T2 (1.0–2.0 mm) 20 35.7
T3 (2.0–4.0 mm) 21 37.5
T4 ([4.0 mm) 8 14.2
Clark level primary tumor
1–3 24 42.6
4–5 31 55.4
Unknown 1 1.8
Localization lymph nodes
Neck 6 10.7
Axilla 20 35.7
Groin 30 53.5
Nodes removed
\15 27 48.2
C15 29 52.8
Positive nodes
\2 36 64.3
C2 20 35.7
Extranodal growth
Yes 24 42.6
No 42 56.4
Lymph node size
\3 cm 28 50.0
C3 cm 28 50.0
Ulceration primary tumor
Yes 13 23.2
No 43 76.8
AJCC stage
IIIa 0 0.0
IIIb 30 53.6
IIIc 26 46.4
TABLE 2 Logistic regression analysis on elevated preoperative S-
100B in stage III melanoma patients
Variable Elevated preoperative
S-100B (%)
OR P value
Sex
Male 51.9 Ref
Female 44.8 0.8 (0.3–2.2) .6
Age
\55 years 44.0 Ref
C55 years 51.6 1.4 (0.5–3.9) .6
Positive lymph nodes
B2 44.4 Ref
[2 55.0 1.5 (0.5–4.6) .5
Extranodal growth
Yes 52.2 Ref
No 48.4 0.9 (0.3–2.5) .8
Tumor size
\3 cm 35.7 Ref
C3 cm 65.4 3.4 (1.1–10.4) .03
Elevated S-100B was deﬁned as S-100B C 0.15 g/L
Ref reference category
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(Table 4). The highest S-100B concentrations were found
in patients with liver and/or skeletal metastases.
20,21 Serum
S-100B concentrations are therefore correlated with the
clinical stage of the disease.
The aim of this study was to evaluate the prognostic
value of preoperative and postoperative concentrations of
the tumor marker S-100B in clinically stage III melanoma
patients who underwent a so-called ‘‘curative lymph node
dissection’’ after preoperative staging with whole-body
FDG-PET and spiral CT. Our results showed that preop-
erative elevated concentrations of S-100B was statistically
signiﬁcantly associated with a decreased DFS. It is difﬁcult
to compare the studies investigating the value of S-100B in
patients with melanoma, because various assays (IRMA or
LIA-mat) and cut-off points and groups of patients with
different stages were used (Table 4).
8 Garbe et al. also
found a relation between S-100B and disease-free survival
TABLE 3 Disease-free
survival (DFS) of AJCC stage
III melanoma patients
Ref reference category
Variable 2-year DFS (%) Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Sex
Male 45 Ref
Female 47 1.2 (0.5–2.6) .7
Localization lymph node
Neck 83 Ref
Axilla 51 3.3 (0.4–26)
Groin 36 4.9 (0.7–37) .2
Positive lymph nodes
B2 64 Ref Ref
[2 23 3.3 (1.5–7.5) .004 1.6 (0.6–4.3) .3
Extranodal growth
Yes 28 Ref Ref
No 58 0.4 (0.2–0.8) .02 0.4 (0.1–1.0) .05
Lymph node size (cm)
\3 53 Ref
C3 35 1.5 (0.7–3.3) .4
Stage
IIIB 69 Ref Ref
IIIC 23 3.9 (1.6–9.5) .003 1.8 (0.6–5.2) .3
Preoperative S-100B
Normal 61 Ref Ref
Elevated 34 2.6 (1.1–6.0) .03 2.6 (1.1–6.1) .03
Postoperative S-100B
No increase 51 Ref Ref
Increase 30 2.0 (0.8–4.8) .1 2.6 (0.9–7.2) .07
1.0
0.8
0.6
0.4
0.2
4 0
Years
3 2 1
Disease-Free
Survival
Normal S-100B
Elevated S-100B
1.0
0.8
0.6
0.4
0.2
4 0
Years
3 2 1
Disease-Free
Survival
No increase postoperative
Increase postoperative
(a) (b) FIG. 1 Kaplan-Meier curve for
preoperative S-100B and
disease-free survival of AJCC
stage III melanoma patients. a
Elevated preoperative S-100B
(34% 2-year DFS) versus not
elevated (61% 2-year DFS)
levels are associated with a
decreased disease-free survival
(P = .03). b Increasing
postoperative S-100B levels
(30% 2-year DFS) versus not
increasing (51% 2-year DFS)
(P = .1)
3458 S. Kruijff et al.in stage II and III melanoma patients. Postoperative ele-
vated S-100B preceded detection of developing metastases
by imaging techniques.
2 According to Martenson et al. and
Curry et al., elevated S-100B in stage III melanoma after
lymph node dissection may form an independent prog-
nostic factor.
20,22 Four studies demonstrated that elevated
S-100B was associated with shortened (disease-free) sur-
vival.
20,23–25 In stage IV patients with normal S-100B
levels, survival was better for patients with low S-100B
levels compared with those with elevated S-100B lev-
els.
15,26 Increasing concentrations of S-100B in stage IV
patients who were receiving systemic treatment were
associated with disease progression.
14,27–29 In a study on
1007 melanoma patients, S-100B was not only correlated
with the clinical stage of the disease, but it also appeared to
be an independent prognostic marker in stages II and III.
The 5-year survival of patients with S-100B values
of\0.10 g/L was 91%, compared with 51% when the
values were[0.10 g/L.
20 In two other studies, similar
patterns were found.
30,31 Two studies comparing 5-S-cy-
steinyldopa, LDH and S-100B as prognostic markers found
that S-100B had the highest speciﬁcity.
30,31
Several studies have therefore recommended the use of
S-100B as a tumor marker to monitor the course of disease
in stage III melanoma patients and to evaluate the effect of
therapy in stage IV patients. Successful treatment with
TABLE 4 Review literature S-100B values above cut-off point in melanoma patients
Reference No. Assay Cut-off value Stage I/II Stage III Stage IV
Guo et al.
14 126 IRMA 0.15 1% 9% 74%
Miliotes et al.
38 67 IRMA 0.05 47.8% – –
Abraha et al.
39 97 IRMA 0.2 9% 82% –
Bosserhoff et al.
40 112 IRMA 0.15 0% 62% –
Buer et al.
24 99 IRMA 3.00 – – 22.2%
Henze et al.
29 73 IRMA 0.3 4% 21% 79%
Tofani et al.
41 53 IRMA 0.5 0% 55% –
Schultz et al.
42 84 IRMA 0.3 0% 31% 69%
Bonfrer et al.
43 251 LIA 0.16 I/II: 1% – III/IV: 79%
Seregni et al.
44 438 IRMA 0.2 I: 4.2%, II: 5.3% 38.5% –
Hauschild et al.
45 412 IRMA 0.2 2% 19% 68%
Curry et al.
22 147 IRMA/LIA 0.2/0.12 – 23%/47.5% –
Berking et al.
46 352 LIA 0.2 7% 8% 48%
Jackel et al.
16 276 LIA 0.12 6% 5% 48%
Kaskel et al.
47 570 LIA 0.11 9% 94% –
Brouard et al.
48 122 LIA 0.09 0% 54% 84%
Vuoristo et al.
49 50 LIA 0.12 – – 64.0%
Jury et al.
50 214 LIA 0.2 7% 29% 92%
Mohammed et al.
21 68 LIA 0.2 – – 73.5%
Martenson et al.
20 727 LIA 0.10 12% – III/IV: 72%
Juergensen et al.
51 50 LIA 0.12 – – I/II/III/IV: 50%
Rebmann et al.
52 183 LIA 0.12 – – I/II/III/IV: 21%
Banfalvi et al.
30 59 LIA 0.12 40% 25% 59%
Garbe et al.
32 296 LIA 0.12
Banfalvi et al.
31 478 LIA 0.18 I: 29%, II: 19% 32% 48%
Andres et al.
53 85 LIA 0.15 – I/II/III: 15% 89%
Ugurel et al.
54 300 LIA 0.12 – – I/II/III/IV: 20%
Smit et al.
15 145 LIA 0.16 – – 78%
Schmidt et al.
55 85 LIA 0.15 – – 59%
Domingo et al.
33 97 LIA 0.15 – II/III: 21% –
Cao et al.
56 42 LIA 0.20 – – 50%
Tarhini et al.
37 670 LIA 0.15 – IIb/III: 13% –
Kruijff et al. 2009 56 LIA 0.15 – 48% –
LIA lumino immunometric assay, IRMA immuno radiometric assay
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was associated with decreased S-100B concentrations,
whereas increased concentrations were an expression of
disease progression.
14,27,28
The prognostic value of the preoperative and postop-
erative course of S-100B concentrations in ‘‘true stage
III’’ melanoma patients has not been studied before. In
advance, we hypothesized that a signiﬁcant decrease in
S-100B concentration after therapeutic lymph node dis-
section would correlate with better DFS. In this way we
assumed S-100B could be used as a quality-control
marker for dissection. In our study, 27 patients (48.2%)
had elevated S-100B preoperatively, and indeed in 22 of
them (81.4%) the concentrations normalized postopera-
tively. However, 12 patients of these 22 (55%) developed
tumor recurrence during a median follow-up of
1.18 years. Multivariate analyses showed that preopera-
tive S-100B elevation was an important predictor of
decreased DFS (P = .03).
Although the results indicated that therapeutic lymph
node dissection did have a temporary inﬂuence on the
postoperative course of S-100B, a more important predictor
for shortened DFS seemed preoperative S-100B elevation.
For AJCC stage III, postoperative increasing S-100B serum
were associated with a decreased DFS. However, when
adjusted for stage III substages, probably because of small
numbers, only a trend toward statistical signiﬁcance was
observed.
S-100B is located in the cytoplasm of melanoma cells.
Elevated serum S100-B occurs as the result of loss of
melanoma cell integrity.
19 Therefore, the hypothesis that
elevation of S-100B should be interpreted as a process of
subclinical microscopic metastatic disease seems to be
suggested by these data. Preoperative elevated S-100B
could be an expression of early dissemination not detected
by standard imaging tests.
33 However, the tumor marker is
not suitable for screening purposes or for the early detec-
tion of recurrence in the follow-up of melanoma patients.
34
The prognostic biochemical marker S-100B may be of
value in the design of future trials on adjuvant systemic
chemotherapy or immunotherapy. At present, LDH is the
most prominent serum parameter in stage IV melanoma,
and it has been included in the new AJCC staging system.
5
Our study on optimally staged clinical stage III melanoma
patients has now shown that preoperative S-100B elevation
is associated with signiﬁcantly poorer survival. These
results are supported by studies from M.D. Anderson
Cancer Center, Barcelona, and a recent meta-analysis and a
pooled analysis of ECOG studies in high-risk surgically
resected melanoma by Kirkwood.
33,35–37 These studies
showed that direct postoperative (baseline) S-100B is
indeed a prognostic marker for disease-free survival (DFS)
and overall survival (OS). Our results seem in accordance
with these data, but more importantly reveal that S-100B is
a prognostic marker for DFS when determined before
dissection. In our study, the 2-year DFS is slightly better
than in the recently published ECOG, which is explained
by the fact that the patients were staged with FDG-PET and
spiral CT.
37 A more reﬁned individualized risk assessment
for adjuvant treatment is possible with serum marker S-
100B. Therefore, S-100B could be included in future
stratiﬁcation research for stage III melanoma.
In summary, preoperative elevation of S-100B levels in
patients with true (clinical) stage III melanoma is associ-
ated with decreased disease-free survival and might have a
prognostic clinical value in high-risk stage III melanoma
patients. Therefore S-100B could be used to select patients
for adjuvant systematic treatment in the stratiﬁcation for
new adjuvant therapeutic trials as well as to provide
information for stage III melanoma patients who want to be
informed about disease prognosis.
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